Nicolas Whenham

570 total citations
17 papers, 234 citations indexed

About

Nicolas Whenham is a scholar working on Genetics, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Nicolas Whenham has authored 17 papers receiving a total of 234 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 8 papers in Pulmonary and Respiratory Medicine and 7 papers in Oncology. Recurrent topics in Nicolas Whenham's work include Glioma Diagnosis and Treatment (8 papers), Brain Metastases and Treatment (5 papers) and Cancer Treatment and Pharmacology (4 papers). Nicolas Whenham is often cited by papers focused on Glioma Diagnosis and Treatment (8 papers), Brain Metastases and Treatment (5 papers) and Cancer Treatment and Pharmacology (4 papers). Nicolas Whenham collaborates with scholars based in Belgium, United States and United Kingdom. Nicolas Whenham's co-authors include Martine Piccart, Véronique D’Hondt, Olivier Féron, Didier Verhoeven, Brieuc Sautois, Sylvie Rottey, Jean‐Marie Vandenbulcke, Emmanuel Seront, Lionel D’Hondt and Jean‐Charles Goeminne and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

Nicolas Whenham

16 papers receiving 230 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicolas Whenham Belgium 7 87 82 79 64 42 17 234
Stephanie Eng Singapore 4 83 1.0× 54 0.7× 71 0.9× 34 0.5× 10 0.2× 5 240
Atulya Aman Khosla United States 8 60 0.7× 61 0.7× 17 0.2× 74 1.2× 70 1.7× 52 221
Christoph Oehler‐Jänne Switzerland 9 95 1.1× 133 1.6× 159 2.0× 61 1.0× 16 0.4× 11 331
Angelo Dipasquale Italy 9 55 0.6× 66 0.8× 15 0.2× 36 0.6× 80 1.9× 23 217
Alessandra Baldoni Italy 6 51 0.6× 127 1.5× 21 0.3× 50 0.8× 46 1.1× 13 224
Hilary S. Serracino United States 6 65 0.7× 189 2.3× 61 0.8× 96 1.5× 14 0.3× 9 334
Sayaka Ueno Japan 10 85 1.0× 85 1.0× 62 0.8× 62 1.0× 11 0.3× 29 309
Nicholas Coupe United Kingdom 7 72 0.8× 139 1.7× 24 0.3× 43 0.7× 16 0.4× 19 220
Laura Ginocchi Italy 8 47 0.5× 119 1.5× 44 0.6× 67 1.0× 5 0.1× 17 183

Countries citing papers authored by Nicolas Whenham

Since Specialization
Citations

This map shows the geographic impact of Nicolas Whenham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Whenham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Whenham more than expected).

Fields of papers citing papers by Nicolas Whenham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Whenham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Whenham. The network helps show where Nicolas Whenham may publish in the future.

Co-authorship network of co-authors of Nicolas Whenham

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Whenham. A scholar is included among the top collaborators of Nicolas Whenham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Whenham. Nicolas Whenham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Whenham, Nicolas, et al.. (2023). Long-term survival in patients with IDH-wildtype glioblastoma: clinical and molecular characteristics. Acta Neurochirurgica. 165(4). 1075–1085. 7 indexed citations
2.
Whenham, Nicolas, et al.. (2023). Health-related quality of life and cognitive failures in patients with lower-grade gliomas treated with radiotherapy. Cancer/Radiothérapie. 27(3). 219–224. 13 indexed citations
3.
Whenham, Nicolas, et al.. (2023). SMART Syndrome: Case Report and Review of the Literature. SHILAP Revista de lepidopterología. 107(1). 49–49. 3 indexed citations
4.
Vanhauwaert, Dimitri, Stephanie Du Four, Liesbet Van Eycken, et al.. (2022). Quality indicators in neuro-oncology: Review of the literature and development of a new quality indicator set for glioma care through a two-round Delphi survey. Journal of Neuro-Oncology. 157(2). 365–376. 6 indexed citations
5.
McCormack, H. A., et al.. (2021). Dietary betaine reduces plasma homocysteine concentrations and improves bone strength in laying hens. British Poultry Science. 62(4). 573–578. 13 indexed citations
6.
Duprez, Thierry, et al.. (2020). Central diabetes insipidus induced by temozolomide: A report of two cases. Journal of Oncology Pharmacy Practice. 27(4). 1040–1045. 5 indexed citations
7.
Fomekong, Edward, et al.. (2019). Long-term survival after glioblastoma resection: hope despite poor prognosis factors. Journal of Neurosurgical Sciences. 63(3). 251–257. 15 indexed citations
8.
9.
Rottey, Sylvie, Aline van Maanen, Jean‐Marie Vandenbulcke, et al.. (2015). Randomized phase II study of cabazitaxel versus methotrexate in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) previously treated with platinum-based therapy.. Journal of Clinical Oncology. 33(15_suppl). 6051–6051. 1 indexed citations
10.
Seront, Emmanuel, Sylvie Rottey, Brieuc Sautois, et al.. (2012). Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers. Annals of Oncology. 23(10). 2663–2670. 102 indexed citations
11.
Awada, Ahmad, Thierry Gil, Nicolas Whenham, et al.. (2011). Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial. The Journal of Clinical Pharmacology. 51(12). 1674–1684. 18 indexed citations
12.
Seront, Emmanuel, Sylvie Rottey, Brieuc Sautois, et al.. (2011). PP 72 Angiogenesis-related cytokines as potential predictive biomarkers in a phase II trial evaluating everolimus efficacy in locally advanced or metastatic Transitional Carcinoma Cell. European Journal of Cancer. 47. S30–S30. 1 indexed citations
13.
Seront, Emmanuel, Brieuc Sautois, Sylvie Rottey, et al.. (2011). Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers.. Journal of Clinical Oncology. 29(15_suppl). 4622–4622. 4 indexed citations
14.
Boterberg, Tom, Paul M. Clément, E. Joosens, et al.. (2011). 8744 POSTER Extended Use of Adjuvant TMZ in Newly Diagnosed GBM Patients is Safe – Results From the Safety Analysis of the PATSGO Trial. European Journal of Cancer. 47. S587–S587. 1 indexed citations
15.
Baurain, Jean‐François, Tom Boterberg, Daniel Devriendt, et al.. (2010). Interim analysis of the randomized PATSGO trial evaluating the prolongation of adjuvant temozolomide in newly diagnosed glioblastoma patients.. Journal of Clinical Oncology. 28(15_suppl). 2044–2044. 2 indexed citations
16.
Seront, Emmanuel, Sylvie Rottey, Brieuc Sautois, et al.. (2010). A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy.. Journal of Clinical Oncology. 28(15_suppl). e15087–e15087. 5 indexed citations
17.
Whenham, Nicolas, Véronique D’Hondt, & Martine Piccart. (2008). HER2-Positive Breast Cancer: From Trastuzumab to Innovatory Anti-HER2 Strategies. Clinical Breast Cancer. 8(1). 38–49. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stephanie Eng Breakdown of academic impact, for papers by Atulya Aman Khosla Breakdown of academic impact, for papers by Christoph Oehler‐Jänne Breakdown of academic impact, for papers by Angelo Dipasquale Breakdown of academic impact, for papers by Alessandra Baldoni Breakdown of academic impact, for papers by Hilary S. Serracino Breakdown of academic impact, for papers by Sayaka Ueno Breakdown of academic impact, for papers by Nicholas Coupe Breakdown of academic impact, for papers by Laura Ginocchi
Rankless by CCL
2026